Objective: to study the influence of Chinese medicines for promoting blood circulation to remove blood stasis on fibrinogen (FIB) and D-dimer (DD) in plasma of patients with cerebral thrombosis. Method: 73 inpatients ...Objective: to study the influence of Chinese medicines for promoting blood circulation to remove blood stasis on fibrinogen (FIB) and D-dimer (DD) in plasma of patients with cerebral thrombosis. Method: 73 inpatients with acute cerebral thrombosis were randomly divided into a control group of 34 cases and a treatment group of 39 cases. The content of FIB and DD in plasma was detected before treatment and on the 7th and 14th days after treatment. Result: FIB content in plasma after treatment was lower than that before treatment in the control group (P<0.01) and more remarkable in the treatment group (P<0.001). There was an obvious difference in DD content before and after treatment in both groups. DD content on the 7th and 14th days after treatment in the treatment group was obviously higher than that in the control group (P<0.01 and P<0.05 respectively). Conclusion: Chinese medicines for promoting blood circulation to remove blood stasis can reduce the FIB content in plasma of patients with cerebral thrombosis, raise the DD content in plasma, cause the peak of DD content appear earlier and obviously improve hypercoagulability of blood in patients with cerebral thrombosis.展开更多
This article presented an overview of the therapeutic effects of Chinese medicine(CM)preparations for promoting blood circulation and removing blood stasis for patients with portal vein thrombosis(PVT)after splenectom...This article presented an overview of the therapeutic effects of Chinese medicine(CM)preparations for promoting blood circulation and removing blood stasis for patients with portal vein thrombosis(PVT)after splenectomy.Based on published clinical researches of CM preparations for PVT after splenectomy in patients with cirrhotic portal hypertension(CPH),this paper evaluated the incidence of PVT,and explored potential active components and mechanisms of CM preparations.Safflower Yellow Injection,Danshen Injection,Danhong Injection,and Compound Danshen Dropping Pill achieved good curative effect alone or combined with anticoagulant therapy.In addition,Compound Biejia Ruangan Tablet and Anluo Huaxian Pill can also significantly improve the hemodynamic disorders of portal vein system in patients with cirrhosis.Considering the role of CM preparations in ameliorating the incidence of PVT after splenectomy in patients with CPH,we suggested that future research should provide more attention to CM alone or CM combined with anticoagulant for cirrhosis with PVT.展开更多
AIM: To observe the therapeutic effects of new traditional Chinese medicine (TCM) therapy on coagulation disorder and accompanying intractable jaundice in HBV-related liver cirrhosis patients. METHODS: Using stratifie...AIM: To observe the therapeutic effects of new traditional Chinese medicine (TCM) therapy on coagulation disorder and accompanying intractable jaundice in HBV-related liver cirrhosis patients. METHODS: Using stratified random sampling according to fibrinogen (Fib) levels,145 liver cirrhosis patients due to hepatitis B complicated by coagulation disorder were treated. Of them,70 in research group were treated with TCM by "nourishing yin,cooling blood and invigorating blood circulation" and Western medicine,75 in control group were treated with conventional Western medicine. The indexes of liver function,coagulation function and bleeding events were observed and compared. RESULTS: The prothrombin time (PT) was shorter and the fibrinogen (Fib) level was higher in the research group than in the control group (Fib = 1.6-2.0 g/L,1.1-1.5 g/L,and ≤ 1.0 g/L). The total bilirubin (TBIL) level was significantly lower in the research group than in the control group,except for the subgroup of FIB ≤ 1.0 g/L. CONCLUSION: TCM therapy can improve coagulation fuction and decrease TBIL.展开更多
In China,traditional Chinese medicine is widely used in the treatment of ischemic stroke,but its prescription rules needs to be further studied.This paper uses the traditional Chinese medicine inheritance auxiliary sy...In China,traditional Chinese medicine is widely used in the treatment of ischemic stroke,but its prescription rules needs to be further studied.This paper uses the traditional Chinese medicine inheritance auxiliary system(a software)to analyze the composition rules of a large number of prescriptions for the treatment of ischemic stroke,and discusses the clinical rationality of the new prescriptions.We found that the prescriptions for the treatment of ischemic stroke are mainly composed by herbs for promoting blood circulation and removing blood stasis,dredging collaterals and tonifying deficiency,and some of the new prescriptions are also in line with this characteristic.This paper can provide reference for clinical prescription in the treatment of ischemic stroke and the development of related new drugs.展开更多
目的 建立活血化瘀类中药注射剂临床使用评价标准。方法 根据《中华人民共和国药典》(2020年版)、《国家基本医疗保险、工伤保险和生育保险药品目录》(2021年版)、《中成药治疗冠心病临床应用指南》(2020版)、《中成药治疗心力衰竭临床...目的 建立活血化瘀类中药注射剂临床使用评价标准。方法 根据《中华人民共和国药典》(2020年版)、《国家基本医疗保险、工伤保险和生育保险药品目录》(2021年版)、《中成药治疗冠心病临床应用指南》(2020版)、《中成药治疗心力衰竭临床应用指南》(2021年版)梳理所有活血化瘀类中药注射剂,根据其药品说明书信息、指南信息和临床使用情况,设立评价指标,运用德尔菲法建立评价标准。收集2022年1月1日至6月30日某院心内科活血化瘀类中药注射剂使用数据,采用评价标准结合优劣解距离法(technique for order preference by similarity to an ideal solution,TOPSIS)进行评价。结果 共纳入21种活血化瘀类中药注射剂适应证,分别从适应证、溶媒、用法用量、辅料和溶剂、配伍使用、特殊人群等方面建立一级、二级评价指标。根据评价结果分析120例心内科使用活血化瘀类中药注射剂患者中,相对接近度(Ci)≥60%的有107例(89.17%),表明某院心内科使用活血化瘀类中药注射剂应用情况基本合理。结论 评价标准的建立有利于提高活血化瘀类中药注射剂使用的合理性,可促进活血化瘀类中药注射剂临床的安全使用。展开更多
文摘Objective: to study the influence of Chinese medicines for promoting blood circulation to remove blood stasis on fibrinogen (FIB) and D-dimer (DD) in plasma of patients with cerebral thrombosis. Method: 73 inpatients with acute cerebral thrombosis were randomly divided into a control group of 34 cases and a treatment group of 39 cases. The content of FIB and DD in plasma was detected before treatment and on the 7th and 14th days after treatment. Result: FIB content in plasma after treatment was lower than that before treatment in the control group (P<0.01) and more remarkable in the treatment group (P<0.001). There was an obvious difference in DD content before and after treatment in both groups. DD content on the 7th and 14th days after treatment in the treatment group was obviously higher than that in the control group (P<0.01 and P<0.05 respectively). Conclusion: Chinese medicines for promoting blood circulation to remove blood stasis can reduce the FIB content in plasma of patients with cerebral thrombosis, raise the DD content in plasma, cause the peak of DD content appear earlier and obviously improve hypercoagulability of blood in patients with cerebral thrombosis.
基金Supported by the National Natural Science Foundation of China(No.81703681,81530101)the Shanghai Sailing Program(No.17YF1419800)。
文摘This article presented an overview of the therapeutic effects of Chinese medicine(CM)preparations for promoting blood circulation and removing blood stasis for patients with portal vein thrombosis(PVT)after splenectomy.Based on published clinical researches of CM preparations for PVT after splenectomy in patients with cirrhotic portal hypertension(CPH),this paper evaluated the incidence of PVT,and explored potential active components and mechanisms of CM preparations.Safflower Yellow Injection,Danshen Injection,Danhong Injection,and Compound Danshen Dropping Pill achieved good curative effect alone or combined with anticoagulant therapy.In addition,Compound Biejia Ruangan Tablet and Anluo Huaxian Pill can also significantly improve the hemodynamic disorders of portal vein system in patients with cirrhosis.Considering the role of CM preparations in ameliorating the incidence of PVT after splenectomy in patients with CPH,we suggested that future research should provide more attention to CM alone or CM combined with anticoagulant for cirrhosis with PVT.
基金Science and Technology Agency of Guangdong Province,NO.2008B030301041
文摘AIM: To observe the therapeutic effects of new traditional Chinese medicine (TCM) therapy on coagulation disorder and accompanying intractable jaundice in HBV-related liver cirrhosis patients. METHODS: Using stratified random sampling according to fibrinogen (Fib) levels,145 liver cirrhosis patients due to hepatitis B complicated by coagulation disorder were treated. Of them,70 in research group were treated with TCM by "nourishing yin,cooling blood and invigorating blood circulation" and Western medicine,75 in control group were treated with conventional Western medicine. The indexes of liver function,coagulation function and bleeding events were observed and compared. RESULTS: The prothrombin time (PT) was shorter and the fibrinogen (Fib) level was higher in the research group than in the control group (Fib = 1.6-2.0 g/L,1.1-1.5 g/L,and ≤ 1.0 g/L). The total bilirubin (TBIL) level was significantly lower in the research group than in the control group,except for the subgroup of FIB ≤ 1.0 g/L. CONCLUSION: TCM therapy can improve coagulation fuction and decrease TBIL.
文摘In China,traditional Chinese medicine is widely used in the treatment of ischemic stroke,but its prescription rules needs to be further studied.This paper uses the traditional Chinese medicine inheritance auxiliary system(a software)to analyze the composition rules of a large number of prescriptions for the treatment of ischemic stroke,and discusses the clinical rationality of the new prescriptions.We found that the prescriptions for the treatment of ischemic stroke are mainly composed by herbs for promoting blood circulation and removing blood stasis,dredging collaterals and tonifying deficiency,and some of the new prescriptions are also in line with this characteristic.This paper can provide reference for clinical prescription in the treatment of ischemic stroke and the development of related new drugs.
文摘目的 建立活血化瘀类中药注射剂临床使用评价标准。方法 根据《中华人民共和国药典》(2020年版)、《国家基本医疗保险、工伤保险和生育保险药品目录》(2021年版)、《中成药治疗冠心病临床应用指南》(2020版)、《中成药治疗心力衰竭临床应用指南》(2021年版)梳理所有活血化瘀类中药注射剂,根据其药品说明书信息、指南信息和临床使用情况,设立评价指标,运用德尔菲法建立评价标准。收集2022年1月1日至6月30日某院心内科活血化瘀类中药注射剂使用数据,采用评价标准结合优劣解距离法(technique for order preference by similarity to an ideal solution,TOPSIS)进行评价。结果 共纳入21种活血化瘀类中药注射剂适应证,分别从适应证、溶媒、用法用量、辅料和溶剂、配伍使用、特殊人群等方面建立一级、二级评价指标。根据评价结果分析120例心内科使用活血化瘀类中药注射剂患者中,相对接近度(Ci)≥60%的有107例(89.17%),表明某院心内科使用活血化瘀类中药注射剂应用情况基本合理。结论 评价标准的建立有利于提高活血化瘀类中药注射剂使用的合理性,可促进活血化瘀类中药注射剂临床的安全使用。
